Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade - sprookjes - yvandenbroek - TriplyDB

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

http://www.wikidata.org/entity/Q27679360

about

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function.Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin Thermodynamic Stabilization of the Folded Domain of Prion Protein Inhibits Prion Infection in Vivo A Nanobody Binding to Non-Amyloidogenic Regions of the Protein Human Lysozyme Enhances Partial Unfolding but Inhibits Amyloid Fibril Formation Fluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging-what we know and what we need to learn Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis Structural evidence for asymmetric ligand binding to transthyretin Small-Molecule Stabilization of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface Protein stability: a crystallographer's perspective First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy Engineering enhanced protein disaggregases for neurodegenerative disease Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies Molecular basis of classic galactosemia from the structure of human galactose 1-phosphate uridylyltransferase.Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.Designed Trpzip-3 β-Hairpin Inhibits Amyloid Formation in Two Different Amyloid Systems Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel.Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial Room-temperature palladium-catalyzed direct 2-arylation of benzoxazoles with aryl and heteroaryl bromides.Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis.Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.Novel drugs targeting transthyretin amyloidosis.FAP neuropathy and emerging treatments.Specific aromatic foldamers potently inhibit spontaneous and seeded Aβ42 and Aβ43 fibril assembly.Recent progress in the understanding and treatment of transthyretin amyloidosis.Surface effects mediate self-assembly of amyloid-β peptides.Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein.Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis.Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy.Identification and characterization of a compound from Cuminum cyminum essential oil with antifibrilation and cytotoxic effect Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models.

P2860

Q26764754-26E9FF9A-D1C1-46E0-98AD-B750586EA6F8 Q27009309-7C40C3CB-3C72-470C-B2BE-5EA96F87C3EC Q27308119-5EEBB384-5F05-4B20-B495-764DF0B1ACCA Q27675997-0766FCCD-2736-4C1E-9E9D-8001D3772BA7 Q27678369-9168F6B4-4B4D-4286-9A08-3FE7E90849A9 Q27679150-A464921B-CF20-4127-9CCF-CE6AE938CB48 Q27679384-5427075B-3F8B-4537-A85D-15E68A815CE8 Q27680199-89115419-51C0-4923-941C-99B673AAEDCB Q27681502-D2F60EC9-658C-45D4-9600-33FEDE667811 Q27701741-9445D4FD-E70D-4738-AAA6-517C1AABF017 Q27703111-AC69E4F6-9BA6-4D62-AC54-759D7F260542 Q28068775-E202A16A-3C4C-4425-80CD-D169D15950A5 Q28071522-0232355B-A487-4E42-BDEA-55E1E794A813 Q28083809-3412B478-97C5-41B7-8B1B-A4FFE29B9193 Q28084013-45B1F9C8-20EF-4A9C-B686-9A48220842D2 Q28539839-A33A638B-1F1B-4CA1-9C4C-AFBFC4A79C1F Q28547541-EAED93AF-4DD7-40A5-AC86-C77ADAAF6619 Q28551432-591B4872-109D-449E-B681-C09718BA1ACA Q28597211-A5A1379C-2C57-46E0-A274-DF9E38097CFD Q30668563-33F253A8-662F-458D-8CB8-8DA4CD6E933D Q33423160-0FDE154C-36BF-4500-8799-266B0E4C7729 Q33635955-3329ED74-56A1-4778-A426-2184EEC5F26D Q33671132-25EC07A5-6873-4ABB-B1C6-8FC09B41AE4F Q33903527-BC9AB42A-3E96-4DA1-85F0-2D7E18360F8E Q34105124-CB44C294-6829-4038-BC7B-20C9CB169250 Q34336131-05389803-E945-4B28-971D-E9D514CF0B01 Q34379670-B0AAE9F3-D0D5-4DB1-9293-3EE30A57D095 Q34400138-000DB8A3-5E23-408E-9185-6FC6D1DFD7C2 Q34401190-6311409A-525E-473C-80A4-3D4E6B886B3F Q34402886-07A77620-C29F-4589-9DED-FEB6F4571FAD Q34416193-E9575ABC-9F3B-4845-AA57-770AE3EAC35C Q34419863-D61934C4-5CF9-485A-9D99-10681568325E Q34422510-5EFB8E36-976F-47C8-8E42-CE4245F35EEC Q34428314-41B53C58-D45A-45C9-A3B5-9C219C73FB77 Q34625989-8B70FD3D-3886-4E0E-94D0-689F058FC8AF Q34838524-32D543C7-3B45-48EB-9894-ADDB419DA8EC Q34923990-7E0252FA-3B6D-45DA-8067-65BB42FB1D7D Q35072784-F4A0AA35-FEF8-4478-B134-7FE3F95998C8 Q35080748-603C5B5E-73E8-4A4D-B2D7-59EF10116F79 Q35082885-D1B2D7B2-51AA-4313-A873-4AB5EF852535

P2860

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

http://www.wikidata.org/entity/Q27679360

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@ast

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@en

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@nl

type

label

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@ast

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@en

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@nl

prefLabel

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@ast

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@en

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@nl

P1433

Q27679360-B0931365-6A35-4D77-814F-7904A7E7D20E

P1476

Q27679360-E7FBB9DC-37E4-4C2D-AF08-BC70ACA50AD9

P2093

Q27679360-08F46D5F-4E9C-45E8-97BD-8EC176CC38F5

Q27679360-3DB77B43-D358-4010-8DCB-20E24F358FED

Q27679360-4678BF3D-E6AC-4CA5-A19E-A9B8DFF5DEB8

Q27679360-5B165CB5-3ACA-484F-905F-BC1B97A07FF9

Q27679360-DDE4C4B6-9E9F-4D0F-AFA6-C160E2CACB68

Q27679360-E67802F0-5779-4D59-BFD7-E725127B1201

Q27679360-F0D59E73-B5BF-4C9F-866A-C93FEC111B65

Q27679360-F550BB5C-6357-47CC-8A78-0F69C6AD108B

Q27679360-FB87D397-34F0-4CA0-B43B-9816AE3BD5B0

P2860

Q27679360-04EEE7BB-1BCE-4DC6-A79F-7CF28F1CE9C9

Q27679360-07AA6097-71D9-4FC4-A220-DED676D60360

Q27679360-091CC776-EC34-4662-803A-EA30DE4560F1

Q27679360-093BCE83-9DD5-445D-B656-3DB17A2635E6

Q27679360-148B6B35-3909-4A85-83BB-C51699106D82

Q27679360-28B9A5C0-9D0C-4ADB-97B6-A23CB2571F5B

Q27679360-2D7591FA-46A7-4608-B4A8-DA64A491059E

Q27679360-3052B402-BDD1-4446-B921-1CCD9CEF1DDA

Q27679360-3294A999-EDCA-49CD-9DF7-B244AE273982

Q27679360-37EDD468-19E0-49D0-8FCD-26324BBABAE9

P304

Q27679360-E311B484-03F0-4491-AF76-6EC8BDE8F3A7

P31

Q27679360-D1FEE86D-F306-4FA5-9E5E-62F39647B802

P3181

Q27679360-7E3ED40F-7102-42D1-A151-74AA9C67941F

P356

Q27679360-28D54E82-A890-4391-8034-31F69D0548BB

P407

Q27679360-23DA5148-7F82-4982-97E2-2358FCCD3D9E

P433

Q27679360-65D3C6C7-D214-459D-B39D-FBD72747BAB1

P478

Q27679360-D6FADE2C-6018-4A5D-A4B6-C5FD1F52ADB5

P50

Q27679360-19856CDA-6B1A-49D6-B824-3CDB1B7C4AEC

Q27679360-3F611CE1-7FA9-4B43-B3EF-18F53357DE1A

Q27679360-73E7C9E9-BE01-4C10-904D-D31EC715ACB0

Q27679360-F23EA637-EE91-4602-BB69-0A70C5518287

P577

Q27679360-7056C0F5-EF3C-42AE-BDAA-D1B2E00F76BD

P5875

Q27679360-EC022C7C-6476-4344-825A-C5B7ABFDEE77

P698

Q27679360-35EDD161-7577-4A56-917B-5B2C49E1B7A0

P921

Q27679360-2E385EF5-9DE7-4195-9FBB-9006CF89C642

Q27679360-B9D18CD3-EB4A-4994-9EEA-DA854D4CA167

P932

Q27679360-6952D504-8492-4B59-BAEB-FAFD8A316D42

P3181

P356

PNAS.1121005109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Tafamidis, a potent and select ...... t inhibits the amyloid cascade

@en

P2093

Charlotte Weigel

http://www.w3.org/2001/XMLSchema#string

Christine E Bulawa

http://www.w3.org/2001/XMLSchema#string

James A Fleming

http://www.w3.org/2001/XMLSchema#string

Jeff Packman

http://www.w3.org/2001/XMLSchema#string

Lan Wang

http://www.w3.org/2001/XMLSchema#string

Michael Devit

http://www.w3.org/2001/XMLSchema#string

R Luke Wiseman

http://www.w3.org/2001/XMLSchema#string

Stephen Connelly

http://www.w3.org/2001/XMLSchema#string

Theodore R Foss

http://www.w3.org/2001/XMLSchema#string

P2860

Fibril in senile systemic amyloidosis is derived from normal transthyretin

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture

Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates

Rational design of potent human transthyretin amyloid disease inhibitors

A comparative analysis of 23 structures of the amyloidogenic protein transthyretin

Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action

Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization

Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis

Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors

Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †

P304

9629-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2025997

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1121005109

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Richard Labaudinière

Ian Andrew Wilson

Jeffery W. Kelly

P577

2012-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225074467

http://www.w3.org/2001/XMLSchema#string

P698

22645360

http://www.w3.org/2001/XMLSchema#string

P921

tafamidis meglumine

P932

3386102

http://www.w3.org/2001/XMLSchema#string